文献速递冠心病

心肌梗死后β受体阻滞剂治疗患者的心率与心血管结局:ABYSS试验二次分析

Heart Rate and Cardiovascular Outcomes in Post-Myocardial Infarction Patients Treated by β-Blockers: A Secondary Analysis of the ABYSS Trial.
PubMed 文献 · Circulation · 2026-06-10

ABYSS试验的预设二次分析纳入3698例稳定期心梗后射血分数≥40%患者,按随机化前心率三分位分组。基线心率与主要终点无关,但较高心率与死亡、心梗、卒中及心衰复合终点风险增加相关;中断β受体阻滞剂导致心率剂量依赖性升高约10-13次/分,且与更差结局一致相关。

要点

  • 心梗后射血分数保留患者中,较高基线心率与死亡、心梗、卒中风险增加独立相关。
  • 中断β受体阻滞剂使随访心率升高约10-13次/分,且在各心率三分位中均与更差结局相关。
  • 结果支持对稳定期心梗后射血分数保留患者继续β受体阻滞剂治疗。

核心结论

  • 在再灌注时代,稳定期心梗后射血分数保留患者中较高心率仍与不良心血管事件和死亡相关。
  • 中断β受体阻滞剂显著升高心率,且无论基线心率如何均一致与更差结局相关,支持继续β受体阻滞剂治疗。

研究设计与样本

  • ABYSS试验的预设二次分析,纳入3698例稳定期心梗后左室射血分数≥40%患者,随机分为继续或中断β受体阻滞剂。
  • 按随机化前心率三分位分组:<60次/分(T1)、60至<68次/分(T2)、≥68次/分(T3)。
  • 中位年龄63.5岁(55.9-71.1),女性621例(17.1%)。

主要发现

  • 基线心率与主要终点无关(22.4% vs 21.8% vs 21.6%;P=0.867)。
  • 较高心率与死亡、心梗或卒中风险增加相关(5.5% vs 6.4% vs 9.2%;P<0.001;T3 vs T1校正HR 1.55,95%CI 1.14-2.12)。
  • 较高心率与死亡、心梗、卒中或心衰复合终点相关(6.5% vs 7.1% vs 10.4%;P=0.007;T3 vs T1校正HR 1.47,95%CI 1.11-1.97)。
  • 全因死亡率随心率三分位升高(2.9% vs 3.4% vs 5.9%;P=0.004;P趋势=0.008)。
  • 中断β受体阻滞剂导致随访期间心率剂量依赖性升高约10-13次/分,且与更差结局的关联在各心率三分位和射血分数类别(40%-49%和>50%)中一致(无显著交互作用)。

临床怎么用

  • 对稳定期心梗后射血分数保留患者,应关注心率并考虑继续β受体阻滞剂治疗以降低心血管事件风险。
  • 中断β受体阻滞剂可导致心率明显升高,且与更差结局相关,临床决策时需权衡。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Heart rate (HR) is a key prognostic factor after myocardial infarction (MI), but its relevance in the modern reperfusion era is uncertain. We aim to evaluate the association between HR and β-blocker interruption on cardiovascular outcomes. METHODS: A prespecified secondary analysis of the ABYSS trial (Assessment of Beta-Blocker Interruption 1 Year After an Uncomplicated Myocardial Infarction), including 3698 stable post-MI patients (left ventricular ejection fraction ≥40%) randomized to continue or interrupt β-blockers, was conducted. Patients were grouped by prerandomization HR tertiles: <60 bpm (T1), 60 to <68 (T2), and ≥68 (T3). We examined associations between HR, treatment strategy, and the primary end point (death, MI, stroke, or cardiovascular rehospitalization), major secondary end points, and on-treatment HR. RESULTS: Median age in the study population was 63.5 years (55.9-71.1), and there were 621 women (17.1%). Baseline HR was not associated with the primary end point (22.4% versus 21.8% versus 21.6%; P=0.867). Higher HR was associated with increased risk of death, MI, or stroke (5.5% versus 6.4% versus 9.2%; P<0.001; T3 versus T1 adjusted hazard ratio, 1.55; 95% CI, 1.14-2.12) and death, MI, stroke, or heart failure (6.5% versus 7.1% versus 10.4%; P=0.007; T3 versus T1 adjusted hazard ratio, 1.47; 95% CI, 1.11-1.97). All-cause mortality rose across tertiles (2.9% versus 3.4% versus 5.9%; P=0.004; P trend=0.008). β-Blocker interruption produced a dose-dependent HR increase of ≈10-13 bpm during follow-up. The association between interruption and worse outcomes was consistent across HR tertiles (no significant interaction) and left ventricular ejection fraction categories (40% to 49% and >50%). CONCLUSIONS: In stabilized post-MI patients with preserved ejection fraction, higher HR remains associated with adverse cardiovascular events and mortality in the reperfusion era. Interrupting β-blockers substantially increases HR and is consistently linked with worse outcomes irrespective of baseline HR, supporting continuation of β-blocker therapy.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Zeitouni, Procopi, Cayla, et al. Heart Rate and Cardiovascular Outcomes in Post-Myocardial Infarction Patients Treated by β-Blockers: A Secondary Analysis of the ABYSS Trial. Circulation. 2026. PMID: 42267437. doi:10.1161/CIRCULATIONAHA.125.078635

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。